UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 25

Sortiert nach

Exploiting Synthetic Lethality between Germline BRCA1 Haploinsufficiency and PARP Inhibition in JAK2V617F-Positive Myeloproliferative Neoplasms

International journal of molecular sciences, 2023-12, Vol.24 (24), p.17560

2023

Volltextzugriff (PDF)

Low Level Her2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate Cancer

Clinical cancer research, 2010-03, Vol.16 (5), p.1553-1560

2010

Volltextzugriff (PDF)

Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation

Journal of neuro-oncology, 2020-03, Vol.147 (1), p.1-14

2020

Volltextzugriff (PDF)

Aging of blood can be tracked by DNA methylation changes at just three CpG sites

Genome biology, 2014-02, Vol.15 (2), p.R24-R24

2014

Volltextzugriff (PDF)

The Fc‐alpha receptor is a new target antigen for immunotherapy of myeloid leukemia

International journal of cancer, 2015-12, Vol.137 (11), p.2729-2738

2015

Volltextzugriff (PDF)

A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy

Haematologica (Roma), 2015-07, Vol.100 (7), p.898

2015

Volltextzugriff (PDF)

Additional benefits of telomere length (TL) measurements in chronic lymphocytic leukemia

Leukemia & lymphoma, 2019-01, Vol.60 (2), p.541-543

2019

Volltextzugriff (PDF)

Kapitel 30 - Ph-negative myeloproliferative Neoplasien

Therapie-Handbuch Onkologie und Hämatologie, 2022, p.212-220

2022

Volltextzugriff (PDF)

Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?

Blood, 2020-08, Vol.136 (7), p.823-830

2020

Volltextzugriff (PDF)

Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry

Journal of cancer research and clinical oncology, 2023-07, Vol.149 (8), p.4611-4621

2023

Volltextzugriff (PDF)

The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib

Leukemia, 2024-02, Vol.38 (2), p.318-325

2024

Volltextzugriff (PDF)

Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia

Blood, 2019-11, Vol.134 (Supplement_1), p.13-13

2019

Volltextzugriff (PDF)

Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML)

Annals of hematology, 2019-06, Vol.98 (6), p.1393-1401

2019

Volltextzugriff (PDF)

Efficacy and Safety of Bosutinib in Previously Treated Patients with Chronic Myeloid Leukemia: Final Results from the Byond Trial

Blood, 2021-11, Vol.138 (Supplement 1), p.1475-1475

2021

Volltextzugriff (PDF)

Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia

Journal of cancer research and clinical oncology, 2017-08, Vol.143 (8), p.1543-1554

2017

Volltextzugriff (PDF)

Phase II Pilot Clinical Trial of Pazopanib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When No Intensive Treatment Is Possible

Blood, 2018-11, Vol.132 (Supplement 1), p.5176-5176

2018

Volltextzugriff (PDF)

Telomere Length Shortening in the CML Leukemic Stem Cell Compartment Correlates with the Respective Clone Size: Evidence for Early Vs. Late Chronic Phase

Blood, 2016-12, Vol.128 (22), p.4243-4243

2016

Volltextzugriff (PDF)

Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemia

Blood advances, 2018-07, Vol.2 (13), p.1572-1579

2018

Volltextzugriff (PDF)

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line

Oncoimmunology, 2019, Vol.8 (9), p.e1638210-e1638210

2019

Volltextzugriff (PDF)

“Duration of Deep Molecular Response” Has Most Impact on the Success of Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia - Results from the EURO-SKI Trial

Blood, 2017-12, Vol.130, p.313-313

2017

Volltextzugriff (PDF)

Immunological Monitoring of CML Patients during First-Line Bosutinib and Imatinib Treatment

BLOOD, 2016-12, Vol.128 (22), p.3069-3069

2016

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(22)

Publikationsform

Artikel
(24)
Buchkapitel
(1)

Sprache

Englisch
(24)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(16)
Science & Technology
(16)
Humans
(13)
Oncology
(11)
Hematology
(10)
Male
(8)
Middle Aged
(8)
Aged
(7)
Female
(7)
Adult
(6)
Treatment Outcome
(5)
Leukemia
(4)
Leukemia, Myelogenous, Chronic, Bcr-Abl Positive - Drug Therapy
(4)
Medical Prognosis
(4)
Medicine
(4)
Medicine & Public Health
(4)
Prognosis
(4)
Aged, 80 And Over
(3)
Imatinib
(3)
Leukemia, Myelogenous, Chronic, Bcr-Abl Positive - Genetics
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Exploiting Synthetic Lethality between Germline BRCA1 Haploinsufficiency and PARP Inhibition in JAK2V617F-Positive Myeloproliferative Neoplasms

Low Level Her2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate Cancer

Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation

Aging of blood can be tracked by DNA methylation changes at just three CpG sites

Detection of Karyotype Evolution From Peripheral Blood by Sequential FISH Analyses of Circulating CD34+ Cells In MDS Patients: Results of the Ongoing German Multicenter Prospective Diagnostic Study

The Fc‐alpha receptor is a new target antigen for immunotherapy of myeloid leukemia

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy

European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission

Additional benefits of telomere length (TL) measurements in chronic lymphocytic leukemia

Kapitel 30 - Ph-negative myeloproliferative Neoplasien

Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?

Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry

The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib

Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia

Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML)

Efficacy and Safety of Bosutinib in Previously Treated Patients with Chronic Myeloid Leukemia: Final Results from the Byond Trial

Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia

Phase II Pilot Clinical Trial of Pazopanib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When No Intensive Treatment Is Possible

Genotypes of the Gene Encoding the Membrane Transporter SLC22A4 Are Associated with Molecular Relapse-Free Survival after Discontinuation of Imatinib Therapy in Patients with Chronic Myeloid Leukemia

Telomere Length Shortening in the CML Leukemic Stem Cell Compartment Correlates with the Respective Clone Size: Evidence for Early Vs. Late Chronic Phase

Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemia

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line

“Duration of Deep Molecular Response” Has Most Impact on the Success of Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia - Results from the EURO-SKI Trial

Immunological Monitoring of CML Patients during First-Line Bosutinib and Imatinib Treatment

Suchergebnisse filtern